Do-Youn Oh

Do-Youn Oh has led pivotal clinical trials establishing immunotherapy-based combination regimens as standards of care for biliary tract cancers. He was a principal investigator for the TOPAZ-1 trial of durvalumab plus gemcitabine-cisplatin in biliary tract cancer and has contributed to multiple immunotherapy trials in this disease. His research has characterized the unique molecular features of biliary tract cancers in Asian populations including high rates of HER2 amplification in gallbladder cancer and distinct FGFR2 fusion prevalence. He has advanced the development of trastuzumab deruxtecan and other HER2-directed therapies in HER2-positive biliary tract cancers.